News & Events
-
January 17, 2012
Barry Grossman gave a presentation on the requirements and methodologies used to Go Private and participated on a panel discussing Privatization of Chinese Companies.
Click here to view the presentation -
January 11, 2012
Ellenoff Grossman & Schole LLP was ranked #4 for issuer representation in IPO transactions (by number of transactions) for 2011.
-
January 4, 2012
Ellenoff Grossman & Schole LLP was ranked #1 for placement agent representation in PIPE transactions (by number of transactions) for 2011.
-
December 30, 2011
AspenBio Pharma, Inc. announced the closing of their registered direct offering in the amount of $1,637,100. EG&S acted as counsel to the Placement Agent.
-
December 28, 2011
Oculus Innovative Sciences, Inc. announced the closing of their registered direct offering in the amount of $2,081,100. EG&S acted as counsel to the Placement Agent.
-
December 28, 2011
Quadrant 4 Systems Corporation announced the closing of their private placement in the amount of $800,000. EG&S acted as counsel to the Investor.
-
December 27, 2011
Catasys, Inc. announced the closing of their registered direct offering in the amount of $974,999. EG&S acted as counsel to the Placement Agent.
-
December 21, 2011
StemCells, Inc. announced the closing of their underwritten public offering in the amount of $10,000,000. EG&S acted as counsel to the Underwriter.
-
December 13, 2011
PhotoMedex, Inc., a NASDAQ listed company, and Radiancy, Inc., a private Delaware company, announced the completion of their merger. Pursuant to the merger, the former stockholders of Radiancy received shares of Photomedex valued on the date of closing at approximately $235 million and collectively own approximately 75% of PhotoMedex, Inc. following the merger. Radiancy became a majority-owned subsidiary of PhotoMedex. EG&S acted as counsel to Radiancy.
-
December 13, 2011
Cell Therapeutics Inc. announced the closing of their registered direct in the amount of $20,000,000. EG&S acted as counsel to the Placement Agent.
